Reduction of Demoralization After Treatment of TD With Valbenazine
Study Details
Study Description
Brief Summary
The purpose of this research project is to determine the feasibility of a larger study aimed at demonstrating that treatment of tardive dyskinesia with Valbenazine is associated with reduction of demoralization
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
This will be an Investigator-initiated, prospective, single center, interventional pilot study. This study will examine the feasibility of a larger study aimed at determining if there is an association between the improvement in tardive dyskinesia and the reduction in demoralization and subjective incompetence in patients with tardive dyskinesia after treatment with Valbenazine. Participants will be treated with Valbenazine for a total of 7 weeks.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Valbenazine All participants will be treated with Valbenazine for 7 weeks. |
Drug: Valbenazine
All participants will be treated with Valbenazine for 7 weeks.
|
Outcome Measures
Primary Outcome Measures
- Change in demoralization Scale [Baseline, week 2, week 4, and week 6]
The change in symptoms of demoralization will be measured using the Demoralization Scale-II (DS-II). Scale scores range from 0 (minimum) to 32 (maximum), with higher scores indicating more demoralization (i.e., a worse outcome). Reduction of score to below 10 will be measured
Secondary Outcome Measures
- Change in subjective incompetence scale (SIS) score [Baseline, week 2, week 4, and week 6]
The SIS consists of 12 items, each item has 4 response alternatives scored as 0, 1, 2, 3. The scores range from 0 to 36. Higher scores mean more severe subjective incompetence.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age: 26-84
-
Sex: Both males and females will be included
-
Diagnosis of dopamine receptor-blocker induced tardive dyskinesia according to the DSM-5 criteria: "involuntary athetoid or choreiform movements lasting at least a few weeks, developing in association with the use of a neuroleptic medication for at least a few months, and persisting beyond 4-8 weeks"
Exclusion Criteria:
The following classes of patients will be excluded:
-
Patients with unstable psychiatric status defined as having a total score on BPRS of 50 or higher
-
Patients who have suicidal or homicidal ideation, intent, or plan or viewed as having a significant risk of suicidal or violent behavior;
-
Patients with cognitive impairment as defined by a score of 24 or less on the MMSE
-
Patients with current diagnosis of alcohol or substance use disorder made according to DSM-5 criteria
-
Patients with clinically significant unstable medical condition defined as follows: a comorbid abnormal movement disorder more prominent than tardive dyskinesia (e.g., parkinsonism, akathisia, truncal dystonia), a score of greater than 2 on two or more items of the Simpson-Angus Scale, or a history of neuroleptic malignant syndrome.
-
Patients previously treated with Valbenazine or any other medication specifically indicated for tardive dyskinesia
-
Patients currently taking strong CYP3A4 inducers, dopamine agonists, MAO inhibitors, stimulants, and/or VMAT2 inhibitors
-
Patients with congenital long QT syndrome or arrhythmias associated with prolonged QT interval
-
Patients with risk factors for prolonged QT such as electrolyte abnormalities (hypokalemia, hypocalcemia, hypomagnesemia), anorexia nervosa, diuretic use, certain heart conditions, and other medical conditions
-
Patients tested positive for Coronavirus Covid-19
-
Patients with impaired decision-making capacity
-
Institutionalized individuals
-
Prisoners
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Yale University
- Neurocrine Biosciences
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2000031135